DNA repair gene XRCC3 Thr241Met polymorphism and susceptibility to glioma: A case‑control study

Xu,Gaofeng; Wang,Maode; Xie,Wanfu; Bai,Xiaobin

doi:10.3892/ol.2014.2192

DNA repair gene XRCC3 Thr241Met polymorphism and susceptibility to glioma: A case‑control study

Authors:
- Gaofeng Xu
- Maode Wang
- Wanfu Xie
- Xiaobin Bai
View Affiliations

Affiliations: Department of Neurosurgery, The First Affiliated Hospital of The Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: May 28, 2014 https://doi.org/10.3892/ol.2014.2192
Pages: 864-868

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The DNA repair gene, X‑ray repair cross‑complementing group 3 (XRCC3) Thr241Met polymorphism may be associated with a susceptibility to glioma. The present study aimed to investigate the association between the XRCC3 Thr241Met polymorphism and the potential susceptibility to gliomas. A hospital‑based case‑control study was conducted, which included a total of 886 patients with glioma and 886 healthy control subjects. Peripheral blood samples were extracted and the polymerase chain reaction‑restriction fragment length polymorphism method was performed to analyze the genotypes. The glioma patients had a significantly higher frequency of the XRCC3 241 MetMet genotype [odds ratio (OR) = 1.62; 95% confidence interval (CI): 1.09‑2.41; P=0.02] compared with the control subjects. When stratified by the grade of the glioma, the patients with stage IV glioma (according to the World Health Organization classification) had a significantly higher frequency of the XRCC3 241 MetMet genotype (OR=1.61; 95% CI: 1.06‑2.44; P=0.03). When stratified by the histology of the glioma, there was no significant difference in the distribution of each genotype. The findings of the present study indicate that the XRCC3 Thr241Met polymorphism is associated with a susceptibility to glioma.

View Figures

View References

1	Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med. 359:492–507. 2008.
2	Ohgaki H and Kleihues P: Epidemiology and etiology of gliomas. Acta Neuropathol. 109:93–108. 2005.
3	Jakola AS, Myrmel KS, Kloster R, et al: Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA. 308:1881–1888. 2012.
4	Reuss D and von Deimling A: Hereditary tumor syndromes and gliomas. Recent Results Cancer Res. 171:83–102. 2009.
5	Moore SC, Rajaraman P, Dubrow R, et al: Height, body mass index, and physical activity in relation to glioma risk. Cancer Res. 69:8349–8355. 2009.
6	Kostron H, Swartz MR, Miller DC and Martuza RL: The interaction of hematoporphyrin derivative, light, and ionizing radiation in a rat glioma model. Cancer. 57:964–970. 1986.
7	Hocking B: Occupational exposure to ionizing and non-ionizing radiation and risk of glioma. Occup Med (Lond). 58:148–149. 2008.
8	Ron E, Modan B, Boice JD Jr, et al: Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med. 319:1033–1039. 1988.
9	Shete S, Hosking FJ, Robertson LB, et al: Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 41:899–904. 2009.
10	Wrensch M, Jenkins RB, Chang JS, et al: Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet. 41:905–908. 2009.
11	Griffin CS, Simpson PJ, Wilson CR and Thacker J: Mammalian recombination-repair genes XRCC2 and XRCC3 promote correct chromosome segregation. Nat Cell Biol. 2:757–761. 2000.
12	Shen MR, Jones IM and Mohrenweiser H: Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res. 58:604–608. 1998.
13	Zhao Y, Deng X, Wang Z, Wang Q and Liu Y: Genetic polymorphisms of DNA repair genes XRCC1 and XRCC3 and risk of colorectal cancer in Chinese population. Asian Pac J Cancer Prev. 13:665–669. 2012.
14	Cheng CX, Xue M, Li K and Li WS: Predictive value of XRCC1 and XRCC3 gene polymorphisms for risk of ovarian cancer death after chemotherapy. Asian Pac J Cancer Prev. 13:2541–2545. 2012.
15	Shaker OG and Sadik NA: Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy. J Gastroenterol Hepatol. 27:1842–1849. 2012.
16	Yin QH, Liu C, Li L, Zu XY and Wang YJ: Association between the XRCC3 T241M polymorphism and head and neck cancer susceptibility: a meta-analysis of case-control studies. Asian Pac J Cancer Prev. 13:5201–5205. 2012.
17	Zhu X, Zhong Z, Zhang X, et al: DNA repair gene XRCC3 T241M polymorphism and bladder cancer risk in a Chinese population. Genet Test Mol Biomarkers. 16:640–643. 2012.
18	Zhao P, Zou P, Zhao L, et al: Genetic polymorphisms of DNA double-strand break repair pathway genes and glioma susceptibility. BMC Cancer. 13:2342013.
19	Pan WR, Li G and Guan JH: Polymorphisms in DNA repair genes and susceptibility to glioma in a chinese population. Int J Mol Sci. 14:3314–3324. 2013.
20	Luo KQ, Mu SQ, Wu ZX, Shi YN and Peng JC: Polymorphisms in DNA repair genes and risk of glioma and meningioma. Asian Pac J Cancer Prev. 14:449–452. 2013.
21	Kiuru A, Lindholm C, Heinävaara S, et al: XRCC1 and XRCC3 variants and risk of glioma and meningioma. J Neurooncol. 88:135–142. 2008.
22	Wang LE, Bondy ML, Shen H, et al: Polymorphisms of DNA repair genes and risk of glioma. Cancer Res. 64:5560–5563. 2004.
23	Zhao B, Ye J, Li B, Ma Q, Su G and Han R: DNA repair gene XRCC3 Thr241Met polymorphism and glioma risk: a meta-analysis. Int J Clin Exp Med. 6:438–443. 2013.
24	Jiang J, Quan XF, Zhang L and Wang YC: The XRCC3 Thr241Met polymorphism influences glioma risk - a meta-analysis. Asian Pac J Cancer Prev. 14:3169–3173. 2013.
25	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007.
26	Duan Z, Shen H, Lee JE, et al: DNA repair gene XRCC3 241Met variant is not associated with risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev. 11:1142–1143. 2002.
27	Fan Z, Wu Y, Shen J and Zhan R: Glutathione S-transferase M1, T1, and P1 polymorphisms and risk of glioma: a meta-analysis. Mol Biol Rep. 40:1641–1650. 2013.
28	Jacobs DI and Bracken MB: Association between XRCC1 polymorphism 399 G→A and glioma among Caucasians: a systematic review and meta-analysis. BMC Med Genet. 13:972012.
29	Sun JY, Zhang CY, Zhang ZJ, et al: Association between XRCC1 gene polymorphisms and risk of glioma development: a meta-analysis. Asian Pac J Cancer Prev. 13:4783–4788. 2012.
30	Wei X, Chen D and Lv T: A functional polymorphism in XRCC1 is associated with glioma risk: evidence from a meta-analysis. Mol Biol Rep. 40:567–572. 2013.
31	Fan W, Li S, Chen Q, Huang Z, Ma Q and Xiao Z: Association between interleukin-10 promoter polymorphisms and endometriosis: a meta-analysis. Gene. 515:49–55. 2013.
32	Zhan P, Wang Q, Qian Q and Yu LK: XRCC3 Thr241Met gene polymorphisms and lung cancer risk: a meta-analysis. J Exp Clin Cancer Res. 32:12013.
33	Wang Z and Zhang W: Association between XRCC3 Thr241Met polymorphism and colorectal cancer risk. Tumour Biol. 34:1421–1429. 2013.
34	Zhu H, Lei X, Liu Q and Wang Y: Interleukin-10-1082A/G polymorphism and inflammatory bowel disease susceptibility: a meta-analysis based on 17,585 subjects. Cytokine. 61:146–153. 2013.
35	Li D, He Q, Li R, Xu X, Chen B and Xie A: Interleukin-10 promoter polymorphisms in Chinese patients with Parkinson’s disease. Neurosci Lett. 513:183–186. 2012.